The Effect of Acute Loading with Selegiline and Selegiline with Levodopa on Blood Pressure and Plasma Norepinephrine Levels in Chronic Parkinsonian Patients

  • Jose M. Rabey
  • Rafael O. Stryjer
Part of the Advances in Behavioral Biology book series (ABBI, volume 53)


Selegiline, an irreversible inhibitor of monoamine oxidase B (MAO B), was introduced as a symptomatic treatment for Parkinson’s disease (PD) in the mid-1970s, with the intention of enhancing the effect of levodopa (LD).1–3


Orthostatic Hypotension Multiple System Atrophy Pure Autonomic Failure Plasma Norepinephrine Level Supine Hypertension 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Birkmayer W, Riederer P, Ambrozi L, et al. Implications of combined treatment with “Madopar” and L- deprenyl in Parkinson’s disease. Lancet 1977;1:439–43.PubMedCrossRefGoogle Scholar
  2. 2.
    Lees AJ, Shaw KM, Kohout LT, et al. Deprenyl in Parkinson’s disease. Lancet 1997;2:791–5.Google Scholar
  3. 3.
    Streifler M, Vardi J, Borenstein N, et al. S. B-type Monoamine oxidase (M.A.O.) inhibitors in long-term levodopa treated Parkinsonism. A combined clinical trial with L-deprenyl. Curr Ther Res Clin Exp 1980;27:643–8.Google Scholar
  4. 4.
    Lees AJ, on behalf of the Parkinsonian’s Disease Research Group of the United Kingdom. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson’s disease. BMJ 1995;311:1602–7.PubMedCrossRefGoogle Scholar
  5. 5.
    Olanow CW, Myllyla VV, Sotaniemi KA, et al. Effects of selegiline on mortality in patients with Parkinson’s disease: a meta-analysis. Neurology 1998;51:825–30.PubMedCrossRefGoogle Scholar
  6. 6.
    Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Neurology 1996;46:1470.Google Scholar
  7. 7.
    Churchyard A, Mathias CJ, Boonkongchuen P, et al. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1997;63:22228–234.CrossRefGoogle Scholar
  8. 8.
    Reynold GP, Elsworth JD, Blau K, et al. Deprenyl is metabolized to metamphetamine and amphetamine in man. Br J Clin Pharmacol 1978;6: 542–4.CrossRefGoogle Scholar
  9. 9.
    Gill JR, Mason DT, Bartter FC. Effects of hydroxyamphetamine (paredrine) on the function of the sympathetic nervous system in normotensive subjects. J Pharmacol Exp Ther 1967;155:288–95.PubMedGoogle Scholar
  10. 10.
    Cavanaugh JH, Griffith JD, Oates JA. Effects of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man. Clin Pharmacol Ther 1970;11:656–64.PubMedGoogle Scholar
  11. 11.
    Waldmeier PC, Feiner AE. Deprenyl: loss of selectivity for inhibition of B-type MAO after repeated treatment. Biochem Pharmacol 1978;27:801–2.PubMedCrossRefGoogle Scholar
  12. 12.
    Gelowitz DL, Richardson JS, Wishart TB, et al. Chronic L-, deprenyl or L- amphetamine: equal cognitive enhancement, unequal MAO inhibition. Pharmacol Biochem Behav 1994;47:41–5.PubMedCrossRefGoogle Scholar
  13. 13.
    Goodman Gilman A, Goodman LS, Rail TW, et al, eds. Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 7th ed. New York: Macmillan Publishing Company, 1985:1786.Google Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • Jose M. Rabey
  • Rafael O. Stryjer
    • 1
  1. 1.Department of NeurologyAssaf Harofeh Medical CenterZerifinIsrael

Personalised recommendations